SODIUM POLYSTYRENE SULFONATE

Post-LOE

Hikma

ANDAORAL, RECTALSUSPENSION

Approved

Nov 1986

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

SODIUM POLYSTYRENE SULFONATE by Hikma is clinical pharmacology as the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. Approved for hyperkalemia. First approved in 1986.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. For the most part, this action occurs in the large intestine, which excretes potassium ions to a…

Indications (1)

hyperkalemia

Company

Worked on SODIUM POLYSTYRENE SULFONATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.